Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05231 (
interleukin-6
)
23,907
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Aim The present study sought insight into the effects of remifentanyl and fentanyl on LPS-induced release of
interleukin-6
(
IL-6
), tumor necrosis factor-alpha (TNF-alpha) and IL-10 in human whole blood. Methods Whole blood was incubated in the presence and absence of remifentanyl and fentanyl. Effects of remifentanyl and fentanyl on spontaneous and endotoxin (lipopolysaccharide; 100 ng ml(-1))-stimulated cytokine release were studied in whole blood from volunteers (n = 10) cultured for 6 h. Results
IL-6
, TNF-alpha and IL-10 concentrations in groups added with LPS were significantly higher than those in control group (P < 0.01).
IL-6
, TNF-alpha and IL-10 concentrations in activation groups treated with remifentanyl or fentanyl were significantly lower than those in LPS treated group (P < 0.05). There were no significant differences on
IL-6
,TNF-alpha and IL-10 concentrations in drug-alone groups compared with control group (P > 0.05). Conclusion
Remifentanyl
or fentanyl alone has no effects on
IL-6
, TNF-alpha and IL-10 production, but could attenuate LPS-induced
IL-6
,TNF-alpha and IL-10 production in human whole blood.
Remifentanyl
and fentanyl could inhibit the expressions of
IL-6
, TNF-alpha and IL-10 induced by LPS.
...
PMID:Effects of remifentanyl and fentanyl on LPS-induced cytokine release in human whole blood in vitro. 1857 57